Treatment of solid paediatric cancers with tropomyosin targeted therapy

Treatment of solid paediatric cancers with tropomyosin targeted therapy

Institute: Nationwide Children’s Hospital, Ohio
Recipient: Professor Timothy Cripe
Funding: $600,000 July 2011 to June 2018

In parallel to the work carried out by Professor Peter Gunning at UNSW Australia, pre-clinical studies led by Professor Tim Cripe at Nationwide Children's Hospital Columbus, Ohio, and funded by The Kids' Cancer Project, have focussed on testing the anti-tumour activity of anti-tropomyosin (ATM) compounds.

The findings from Professor Cripe’s research provide critical information on this class of drugs, importantly as they confirm for the first time that ATMs can enhance the efficacy of standard-of-care chemotherapy used to treat paediatric neuroblastoma, resulting in a significant reduction of tumour growth and proliferation.